141
Participants
Start Date
March 1, 2020
Primary Completion Date
December 31, 2020
Study Completion Date
April 30, 2021
Selegiline
Subjects will receive one Selegiline tablet (5 mg) per day administered at breakfast. The initial dose of Selegiline is 5 mg/day and be up-titrated in 2-week intervals in increments of 5 mg up to 10 mg (which can be taken at breakfast or divided doses of 5 mg each taken at breakfast and lunch) according to the investigator's judgment, based on individual clinical response and tolerability.
Department of Neurology, Second Affiliated Hospital of Soochow University, Suzhou
Changshu Hospital Affiliated to Nanjing University of Chinese Medicine, Changshu
Second Affiliated Hospital of Nantong University, Nantong
Jiang Yuan Hospital Affiliated to Jiangsu Institute of Nuclear Medicine, Wuxi
Second Affiliated Hospital of Soochow University
OTHER